Advertisement
News
Advertisement

Moffitt Cancer Center and CvergenX, Inc. Sign Licensing Agreement

Tue, 07/27/2010 - 8:33am
Bio-Medicine.Org

TAMPA, Fla., July 27 /PRNewswire/ -- Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.  

"While genomic analysis has been applied in the development of diagnostic tools to guide chemotherapy use, this is the first time that the field has expanded to radiation therapy," said Dr. Javier F. Torres-Roca, the radiation oncologist who co-founded CvergenX with Steven A. Eschrich, Ph.D., both Moffitt faculty members.  "Radiation therapy has undergone vast changes with significant improvements in

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading